No difference was found between both groups regarding gender (p = 0.324, χ2 test), T stage (p = 0.197, χ2 test), BRAF mutation status (p = 0.366, χ2 test), ECOG performance status (p = 0.256, χ2 test), tumour thickness (p = 0.447, Mann-Whitney U Test), immune-related side effects (p = 0.498, χ2 test), or metastases in spleen (p = 0.677, Fisher’s exact test), lymph nodes (p = 0.978, χ2 test), NLR (p = 0.318, Fisher’s exact test), or elevation of eosinophils under therapy (p = 0.165, χ2 test). The gene discussed is BRAF; the disease is neoplasm.